HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs.

Abstract
B72.3, a monoclonal antibody with reactivity against human adenocarcinomas, was coupled with linker-chelator GYK-DTPA using carbohydrate mediated conjugation chemistry and radiolabeled with yttrium-90. Single and double intravenous injections of radioimmunoconjugate were compared for acute and late normal tissue toxicity in 15 beagle dogs. The second injection was given 4 or 8 days after the first. Pharmacokinetics of the radioimmunoconjugate in blood, bone marrow and urine were similar for first and second injections. Only bone marrow (acute) and liver (late) toxicity were observed. Both liver and bone marrow toxicity were decreased by fractionation of the injections. After double injections, the total equitoxic dose was 15 and 60% higher for bone marrow and liver toxicity, respectively. The mechanisms of normal tissue protection offered by fractionated radioimmunoglobulin therapy (RIT) remain to be defined. Fractionated RIT will have a better therapeutic ratio than single injection RIT, if antitumor effects appear to be less susceptible to fractionation than normal tissues.
AuthorsH M Vriesendorp, Y Shao, J E Blum, S M Quadri, J R Williams
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 20 Issue 5 Pg. 571-8 (Jul 1993) ISSN: 0969-8051 [Print] United States
PMID8358342 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Oligopeptides
  • Yttrium Radioisotopes
  • glycyl-tyrosyl-lysine-DTPA
  • Pentetic Acid
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Neoplasm (administration & dosage)
  • Dogs
  • Female
  • Half-Life
  • Infusions, Intravenous
  • Male
  • Oligopeptides (administration & dosage, pharmacokinetics, toxicity)
  • Pentetic Acid (administration & dosage, analogs & derivatives, pharmacokinetics, toxicity)
  • Yttrium Radioisotopes (administration & dosage, pharmacokinetics, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: